CD19-directed chimeric antigen receptor T (CD19 CAR-T) cell is a new modality for the treatment of B-ALL, B-cell lymphoma and chronic lymphocytic leukemia [3–5]. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.